The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

The Agony of Choice—Where to Place the Wave of BCMA-Targeted Therapies in the Multiple Myeloma Treatment Puzzle in 2022 and Beyond

Since the introduction of first-generation proteasome inhibitors and immunomodulatory agents, the multiple myeloma (MM) treatment landscape has undergone a remarkable development. Most recently, immunotherapeutic strategies targeting the B cell maturation antigen (BCMA) entered the clinical stage pr...

Full description

Bibliographic Details
Main Authors: Irene Strassl, Martin Schreder, Normann Steiner, Jakob Rudzki, Hermine Agis, Tina Künz, Nino Müser, Wolfgang Willenbacher, Andreas Petzer, Peter Neumeister, Maria Theresa Krauth
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Cancers
Subjects:
multiple myeloma
BCMA
CAR-T
bispecific antibodies
BiTEs<sup>®</sup>
antibody-drug conjugates (ADC)
Online Access:https://www.mdpi.com/2072-6694/13/18/4701

Internet

https://www.mdpi.com/2072-6694/13/18/4701

Similar Items